
    
      This is a randomized, double-blind, chronic dosing (4 weeks), four-period, five-treatment,
      incomplete block, cross-over, multicenter study to assess the efficacy and safety of four
      doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult
      subjects with mild to moderate persistent asthma.
    
  